1
|
Liu J, Yang S, Cao B, Zhou G, Zhang F, Wang Y, Wang R, Zhu L, Meng Y, Hu C, Liang H, Lin X, Zhu K, Chen G, Luo KQ, Di L, Zhao Q. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. J Hematol Oncol 2021; 14:21. [PMID: 33514401 PMCID: PMC7844995 DOI: 10.1186/s13045-020-01024-8] [Citation(s) in RCA: 46] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Accepted: 12/07/2020] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND B7-H3, an immune-checkpoint molecule and a transmembrane protein, is overexpressed in non-small cell lung cancer (NSCLC), making it an attractive therapeutic target. Here, we aimed to systematically evaluate the value of B7-H3 as a target in NSCLC via T cells expressing B7-H3-specific chimeric antigen receptors (CARs) and bispecific killer cell engager (BiKE)-redirected natural killer (NK) cells. METHODS We generated B7-H3 CAR and B7-H3/CD16 BiKE derived from an anti-B7-H3 antibody omburtamab that has been shown to preferentially bind tumor tissues and has been safely used in humans in early-phase clinical trials. Antitumor efficacy and induced-immune response of CAR and BiKE were evaluated in vitro and in vivo. The effects of B7-H3 on aerobic glycolysis in NSCLC cells were further investigated. RESULTS B7-H3 CAR-T cells effectively inhibited NSCLC tumorigenesis in vitro and in vivo. B7-H3 redirection promoted highly specific T-cell infiltration into tumors. Additionally, NK cell activity could be specially triggered by B7-H3/CD16 BiKE through direct CD16 signaling, resulting in significant increase in NK cell activation and target cell death. BiKE improved antitumor efficacy mediated by NK cells in vitro and in vivo, regardless of the cell surface target antigen density on tumor tissues. Furthermore, we found that anti-B7-H3 blockade might alter tumor glucose metabolism via the reactive oxygen species-mediated pathway. CONCLUSIONS Together, our results suggest that B7-H3 may serve as a target for NSCLC therapy and support the further development of two therapeutic agents in the preclinical and clinical studies.
Collapse
MESH Headings
- Animals
- Antibodies, Bispecific/immunology
- Antibodies, Bispecific/therapeutic use
- B7-H1 Antigen/immunology
- Carcinoma, Non-Small-Cell Lung/immunology
- Carcinoma, Non-Small-Cell Lung/therapy
- Cell Line, Tumor
- Female
- Humans
- Immunotherapy, Adoptive/methods
- Killer Cells, Natural/immunology
- Lung Neoplasms/immunology
- Lung Neoplasms/therapy
- Lymphocyte Activation
- Mice, Inbred NOD
- Mice, SCID
- Receptors, Chimeric Antigen/immunology
- Receptors, Chimeric Antigen/therapeutic use
- T-Lymphocytes/immunology
- T-Lymphocytes/transplantation
- Mice
Collapse
Affiliation(s)
- Jie Liu
- Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
- Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
| | - Shuo Yang
- Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
- Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
| | - Bihui Cao
- Department of Minimally Invasive Interventional Radiology and Department of Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
| | - Guangyu Zhou
- Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
- Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
| | - Fengjuan Zhang
- Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
- Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
| | - Yuan Wang
- Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
- Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
| | - Rixin Wang
- Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
- Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
| | - Lipeng Zhu
- Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
- Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
| | - Ya Meng
- Zhuhai People's Hospital Affiliated with Jinan University, Zhuhai, Guangdong, China
| | - Cong Hu
- Zhuhai People's Hospital Affiliated with Jinan University, Zhuhai, Guangdong, China
| | - Hui Liang
- Zhuhai People's Hospital Affiliated with Jinan University, Zhuhai, Guangdong, China
| | - Xu Lin
- Zhuhai People's Hospital Affiliated with Jinan University, Zhuhai, Guangdong, China
| | - Kangshun Zhu
- Department of Minimally Invasive Interventional Radiology and Department of Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
| | - Guokai Chen
- Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
- Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
| | - Kathy Qian Luo
- Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
- Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
| | - Lijun Di
- Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
- Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China
| | - Qi Zhao
- Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China.
- Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau SPR, China.
| |
Collapse
|